Tempus AI's financials have significantly improved, with positive cash flow expected next quarter. Read why TEM stock is a ...

Linh H. Le is an accomplished finance and accounting executive with extensive knowledge and expertise that he has implemented ...

A detailed genetic investigation has not yet addressed this question.Methods: 350 male volunteers from the Zhetiru tribe were analyzed using 23 Y-STR loci and 17 Y-SNPs. We calculated genetic ...

The increasing use of massive parallel sequencing of customized multi-gene panels, for germline clinical testing of hereditary breast and ovarian cancer (HBOC) and Lynch syndrome, is leading to higher ...

The company recently acquired genetic testing pioneer Ambry Genetics in a strategic move to utilize its diagnostics and data to fuel innovation and enhance solutions for patients, clinicians ...

Familial hypertension can be genetic, meaning you can get a gene from a parent that increases your risk of developing high blood pressure. You may also be more prone to developing high blood pressure ...

Tempus AI TEM, an innovator in artificial intelligence-based healthcare solutions, has been attracting investors' interest since its successful IPO in June 2024. The stock had been on a strong upward ...

For the full year, the Data and Services division was a key contributor. The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus’ genomics capabilities by ...

While there are strong links between asthma and genetics, not everyone with a family history of asthma will develop it. Asthma can also occur in people with no family history of the condition.

"We believe guidance for the year is appropriately set to be achieved and that Tempus has a very long revenue growth runway ahead of it," he said in a report. "Still, shares are o ...

Adjusted EBITDA for 2025: Expected to be approximately $5 million. Acquisition: Closed the acquisition of Ambry Genetics on February 3. Google Agreement: Extended for another five years.